Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the phase I part is to determine the tolerability, the initial safety profile
and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent
lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine
and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent
lymphoma.